Sino Biopharma Invests in Karolinska; Deals Ahead?

Sino Biopharmaceutical will make an investment of up to $128.5 million in Karolinska Development AB, a Stockholm firm that supports translational drug development in Scandinavia. Typically, Karolinska invests in innovative academic-based concepts, bringing them to a point where they can be partnered. It currently has at least a dozen companies in its portfolio. According to Karolinska, it wanted to have a "strong Asian specialist investor" in life science, with the clear implication that future deals would be made between the two companies. More details.... Stock Symbols: (HK: 1177) (SS: KDEV) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.